Q3 EPS Estimates for Co-Diagnostics Lowered by HC Wainwright

Co-Diagnostics, Inc. (NASDAQ:CODX) – Stock analysts at HC Wainwright lowered their Q3 2025 earnings per share estimates for shares of Co-Diagnostics in a research note issued to investors on Tuesday, August 19th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.19) per share for the quarter, down from their prior forecast of ($0.16). The consensus estimate for Co-Diagnostics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Co-Diagnostics’ Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.79) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.39) EPS.

CODX has been the subject of several other reports. D Boral Capital upgraded Co-Diagnostics to a “strong-buy” rating in a report on Monday, April 28th. D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Co-Diagnostics in a research report on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $5.50.

Co-Diagnostics Price Performance

CODX opened at $0.2818 on Thursday. The stock has a 50-day moving average price of $0.27 and a 200-day moving average price of $0.37. The firm has a market cap of $10.85 million, a PE ratio of -0.25 and a beta of 0.51. Co-Diagnostics has a 1 year low of $0.2275 and a 1 year high of $2.2299.

Co-Diagnostics (NASDAQ:CODX) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. The company had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.30 million. Co-Diagnostics had a negative net margin of 3,588.33% and a negative return on equity of 69.49%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Co-Diagnostics stock. Jane Street Group LLC lifted its stake in shares of Co-Diagnostics, Inc. (NASDAQ:CODX) by 314.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 166,254 shares of the company’s stock after acquiring an additional 126,105 shares during the quarter. Jane Street Group LLC owned approximately 0.50% of Co-Diagnostics worth $47,000 at the end of the most recent reporting period. Institutional investors own 14.99% of the company’s stock.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.